pubmed-article:16864853 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C0040732 | lld:lifeskim |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C0280803 | lld:lifeskim |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C0439859 | lld:lifeskim |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
pubmed-article:16864853 | lifeskim:mentions | umls-concept:C1328050 | lld:lifeskim |
pubmed-article:16864853 | pubmed:issue | 24 | lld:pubmed |
pubmed-article:16864853 | pubmed:dateCreated | 2006-8-21 | lld:pubmed |
pubmed-article:16864853 | pubmed:abstractText | To improve survival and reduce toxicity in primary CNS lymphoma (PCNSL) treatment, we conducted a multicenter phase II study with early high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) followed by hyperfractionated whole-brain radiotherapy (WBRT) for newly diagnosed PCNSL patients younger than 65 years of age. | lld:pubmed |
pubmed-article:16864853 | pubmed:language | eng | lld:pubmed |
pubmed-article:16864853 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16864853 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:16864853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16864853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16864853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16864853 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:16864853 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:16864853 | pubmed:month | Aug | lld:pubmed |
pubmed-article:16864853 | pubmed:issn | 1527-7755 | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:FinkeJürgenJ | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:FrickhofenNor... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:GuttenbergerR... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:VolkBenediktB | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:OstertagChris... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:IhorstGabriel... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:FeuerhakeFrie... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:MarksReinhard... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:IllerhausGera... | lld:pubmed |
pubmed-article:16864853 | pubmed:author | pubmed-author:DerigsGünther... | lld:pubmed |
pubmed-article:16864853 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:16864853 | pubmed:day | 20 | lld:pubmed |
pubmed-article:16864853 | pubmed:volume | 24 | lld:pubmed |
pubmed-article:16864853 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:16864853 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:16864853 | pubmed:pagination | 3865-70 | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:meshHeading | pubmed-meshheading:16864853... | lld:pubmed |
pubmed-article:16864853 | pubmed:year | 2006 | lld:pubmed |
pubmed-article:16864853 | pubmed:articleTitle | High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. | lld:pubmed |
pubmed-article:16864853 | pubmed:affiliation | Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany. | lld:pubmed |
pubmed-article:16864853 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:16864853 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:16864853 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16864853 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16864853 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16864853 | lld:pubmed |